X4 Pharmaceuticals (XFOR) Set to Announce Quarterly Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR) is set to issue its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Tuesday, May 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock traded up $0.03 during mid-day trading on Tuesday, hitting $0.64. The stock had a trading volume of 721,071 shares, compared to its average volume of 2,473,582. The firm’s 50 day moving average is $0.84 and its 200 day moving average is $0.97. X4 Pharmaceuticals has a one year low of $0.53 and a one year high of $1.82. The firm has a market capitalization of $107.40 million, a P/E ratio of -0.90 and a beta of 0.35. The company has a current ratio of 3.71, a quick ratio of 3.71 and a debt-to-equity ratio of 52.92.

Analysts Set New Price Targets

Several equities analysts have commented on XFOR shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of X4 Pharmaceuticals in a research report on Friday, May 31st. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of X4 Pharmaceuticals in a research note on Friday, June 28th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.